Schnurr, Alexander
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Publication Access status: Open Access , A toolbox to demystify probabilistic and statistical paradoxes(2023); ; There is a variety of empirical evidence that the coverage of paradoxes in mathematics education helps to support thorough understanding of probabilistic and statistical concepts. However, existing literature often focuses on extensive analysis of a specific paradox, provides new perspectives or an analysis from a different angle. Often neglected aspects in this context are common features between different paradoxes and the fact, that the same situation might look paradoxical to different people for entirely different reasons. We develop a toolbox to demystify paradoxes in probability and statistics. Therefore, we first analyze in which steps of stochastic modeling one might be faced with a paradoxical situation. Secondly, we build on a representative selection of well-known paradoxes and isolate the techniques and methods which help to explain why people find the paradox surprising, identify the class of scenarios where the paradox may occur and make a choice between the seemingly contradictory conclusions. Thirdly, we present the toolbox, which helps to demystify various paradoxical situations. This helps teachers to chose appropriate problems and students to find the right method to resolve these problems. While the developed toolbox is not exhaustive, it helps to dissect the anatomy of probabilistic and statistical paradoxes.Source Type:Article1 3 - Some of the metrics are blocked by yourconsent settings
Publication Access status: Metadata only , The Bayesian Group-Sequential Predictive Evidence Value Design for Phase II Clinical Trials with Binary Endpoints(2024); In clinical research, the initial efficacy of a new agent is typically assessed in a phase IIA study. Bayesian group-sequential designs are often based on predictive probability of trial success. In this paper, the novel Bayesian group-sequential predictive evidence value design is introduced, and we prove that the predictive probability approach is a special case of it. A comparison with Simon’s two-stage and competing Bayesian designs based on phase IIA cancer trials is provided. Results show that the novel design can improve operating characteristics such as the false-positive rate, probability of early stopping for futility and expected sample size of the trial. Given these advantages, the predictive evidence value design constitutes an important addition to the biostatistician’s toolbelt when planning a phase IIA trial the Bayesian way, in particular, when small sample sizes and a large probability for early termination under the null hypothesis are desired.Source Type:Article1
